Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elisabeth De Kermadec

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Presse Medicale (Paris, France : 1983)|September 21, 2013
[Vitamin D and cancers]Marc Espié, Johanna Wassermann, Elisabeth de Kermadec, et al.
Cancer Medicine|December 22, 2023
Fertility concerns and treatment decision-making among national sample of young women with breast cancerElisabeth de Kermadec, Yue Zheng, Shoshana Rosenberg, et al.
Future Oncology (London, England)|December 29, 2025
OPERA-01: a phase III study of palazestrant for ER+, HER2- advanced breast cancer after CDK4/6 inhibitor therapyBarbara Pistilli, Meritxell Bellet Ezquerra, Lucia Del Mastro, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 22, 2023
AMEERA-3: Randomized Phase II Study of Amcenestrant (Oral Selective Estrogen Receptor Degrader) Versus Standard Endocrine Monotherapy in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast CancerSara M Tolaney, Arlene Chan, Katarina Petrakova, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Presse Medicale (Paris, France : 1983)|September 21, 2013
[Vitamin D and cancers]Marc Espié, Johanna Wassermann, Elisabeth de Kermadec, et al.
Cancer Medicine|December 22, 2023
Fertility concerns and treatment decision-making among national sample of young women with breast cancerElisabeth de Kermadec, Yue Zheng, Shoshana Rosenberg, et al.
Future Oncology (London, England)|December 29, 2025
OPERA-01: a phase III study of palazestrant for ER+, HER2- advanced breast cancer after CDK4/6 inhibitor therapyBarbara Pistilli, Meritxell Bellet Ezquerra, Lucia Del Mastro, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 22, 2023
AMEERA-3: Randomized Phase II Study of Amcenestrant (Oral Selective Estrogen Receptor Degrader) Versus Standard Endocrine Monotherapy in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast CancerSara M Tolaney, Arlene Chan, Katarina Petrakova, et al.
Pageof 1